These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30017723)

  • 1. Therapeutic effect of vitamin D
    Zai K; Hirota M; Yamada T; Ishihara N; Mori T; Kishimura A; Suzuki K; Hase K; Katayama Y
    J Control Release; 2018 Sep; 286():94-102. PubMed ID: 30017723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The vitamin D analog TX527 ameliorates disease symptoms in a chemically induced model of inflammatory bowel disease.
    Verlinden L; Leyssens C; Beullens I; Marcelis S; Mathieu C; De Clercq P; Verstuyf A
    J Steroid Biochem Mol Biol; 2013 Jul; 136():107-11. PubMed ID: 23000190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis.
    Beloqui A; Coco R; Alhouayek M; Solinís MÁ; Rodríguez-Gascón A; Muccioli GG; Préat V
    Int J Pharm; 2013 Oct; 454(2):775-83. PubMed ID: 23694806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Lipid-Based Nanocarrier Containing Active Vitamin D
    Mu Y; Li J; Kang JH; Eto H; Zai K; Kishimura A; Hyodo F; Mori T; Katayama Y
    Biol Pharm Bull; 2020; 43(9):1413-1420. PubMed ID: 32879216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Process, optimization, and characterization of budesonide-loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease.
    Sinhmar GK; Shah NN; Chokshi NV; Khatri HN; Patel MM
    Drug Dev Ind Pharm; 2018 Jul; 44(7):1078-1089. PubMed ID: 29376433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease.
    Beloqui A; Memvanga PB; Coco R; Reimondez-Troitiño S; Alhouayek M; Muccioli GG; Alonso MJ; Csaba N; de la Fuente M; Préat V
    Colloids Surf B Biointerfaces; 2016 Jul; 143():327-335. PubMed ID: 27022873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surface engineered lipid nanoparticle-mediated site-specific drug delivery system for the treatment of inflammatory bowel disease.
    Sinhmar GK; Shah NN; Rawal SU; Chokshi NV; Khatri HN; Patel BM; Patel MM
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):565-578. PubMed ID: 29661024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of nanostructured lipid carriers for the encapsulation and controlled release of vitamin D3.
    Park SJ; Garcia CV; Shin GH; Kim JT
    Food Chem; 2017 Jun; 225():213-219. PubMed ID: 28193417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,25‑Dihydroxyvitamin D regulates macrophage polarization and ameliorates experimental inflammatory bowel disease by suppressing miR-125b.
    Zhu X; Zhu Y; Li C; Yu J; Ren D; Qiu S; Nie Y; Yu X; Xu X; Zhu W
    Int Immunopharmacol; 2019 Feb; 67():106-118. PubMed ID: 30540970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum 24,25-dihydroxyvitamin D
    Graeff-Armas LA; Kaufmann M; Lyden E; Jones G
    Clin Nutr; 2018 Jun; 37(3):1041-1045. PubMed ID: 28506446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral delivery of oleuropein-loaded lipid nanocarriers alleviates inflammation and oxidative stress in acute colitis.
    Huguet-Casquero A; Xu Y; Gainza E; Pedraz JL; Beloqui A
    Int J Pharm; 2020 Aug; 586():119515. PubMed ID: 32544520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Vitamin D3 on Intestinal Flora in a Mouse Model of Inflammatory Bowel Disease Treated with Rifaximin.
    Gu Z; Duan M; Sun Y; Leng T; Xu T; Gu Y; Gu Z; Lin Z; Yang L; Ji M
    Med Sci Monit; 2020 Nov; 26():e925068. PubMed ID: 33177483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery.
    Li H; Chen M; Su Z; Sun M; Ping Q
    Int J Pharm; 2016 Sep; 511(1):524-537. PubMed ID: 27452421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue.
    Hua S; Marks E; Schneider JJ; Keely S
    Nanomedicine; 2015 Jul; 11(5):1117-32. PubMed ID: 25784453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and Characterization of Nanostructured Lipid Carrier (NLC) and Nanoemulsion Containing Vitamin D3.
    Jafarifar Z; Rezaie M; Sharifan P; Jahani V; Daneshmand S; Ghazizadeh H; Ferns GA; Golmohammadzadeh S; Ghayour-Mobarhan M
    Appl Biochem Biotechnol; 2022 Feb; 194(2):914-929. PubMed ID: 34581963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted delivery of vitamin D to the colon using β-glucuronides of vitamin D: therapeutic effects in a murine model of inflammatory bowel disease.
    Goff JP; Koszewski NJ; Haynes JS; Horst RL
    Am J Physiol Gastrointest Liver Physiol; 2012 Feb; 302(4):G460-9. PubMed ID: 22114117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoregulation of Inflammatory and Inhibitory Cytokines by Vitamin D3 in Patients with Inflammatory Bowel Diseases.
    Alhassan Mohammed H; Mirshafiey A; Vahedi H; Hemmasi G; Moussavi Nasl Khameneh A; Parastouei K; Saboor-Yaraghi AA
    Scand J Immunol; 2017 Jun; 85(6):386-394. PubMed ID: 28332200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot Study Evaluating Efficacy of 2 Regimens for Hypovitaminosis D Repletion in Pediatric Inflammatory Bowel Disease.
    Simek RZ; Prince J; Syed S; Sauer CG; Martineau B; Hofmekler T; Freeman AJ; Kumar A; McElhanon BO; Schoen BT; Tenjarla G; McCracken C; Ziegler TR; Tangpricha V; Kugathasan S
    J Pediatr Gastroenterol Nutr; 2016 Feb; 62(2):252-8. PubMed ID: 26196201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol.
    Qi R; Li YZ; Chen C; Cao YN; Yu MM; Xu L; He B; Jie X; Shen WW; Wang YN; van Dongen MA; Liu GQ; Banaszak Holl MM; Zhang Q; Ke X
    J Control Release; 2015 Jul; 210():160-8. PubMed ID: 26003044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.